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We read with great interest the recent guidelines from
the European Association for the Study of Liver (EASL)
for the management of chronic hepatitis B [1], which
were eagerly anticipated. We think that they deﬁnitely
represent a step forward in the right direction for the
management of chronic hepatitis B, which is a rapidly
evolving ﬁeld. However, we would like to draw your
attention on the indications for liver biopsy, which re-main a controversial unresolved issue, at least in our
opinion.
In the recent EASL guidelines, ‘‘a liver biopsy is rec-
ommended for determining the degree of necroinﬂam-
mation and ﬁbrosis in patients with either increased
ALT or HBV DNA levels >2000 IU/ml (or both) since
hepatic morphology can assist the decision to start treat-
ment” and this recommendation is graded as A1 (strong
recommendation based on high quality evidence) [1].
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DNA >2000 IU/ml, this recommendation suggests that
almost all HBeAg-positive cases should undergo a liver
biopsy regardless of ALT levels. In the 2002 EASL Con-
sensus Conference on hepatitis B and in all recent guide-
lines including EASL’s [1–3], HBeAg-positive patients
with high HBV DNA and normal ALT activity are con-
sidered to be within the ﬁrst immunotolerant phase of
chronic HBV infection and to have no or minimal histo-
logical changes. To our knowledge, strong data to
change this concept have not been recently reported
and therefore the vast majority of such patients are
not expected to beneﬁt from a liver biopsy showing min-
imal changes. The decision to treat such patients with
very high viremia may be generally a matter of debate
for several reasons, but the histological ﬁndings are
not going to reveal lesions that require therapeutic inter-
vention [1–3] [at least moderate necroinﬂammation and/
or ﬁbrosis [1]].
The issue of liver biopsy in HBeAg-negative chronic
HBV patients with persistently normal ALT activity
has always been debatable. It is widely accepted that
liver biopsy is not required in such patients with
HBV DNA <2000 IU/ml [1,3,4], while HBeAg-negative
patients with HBV DNA >2000 IU/ml appear to repre-
sent a controversial group. According to studies from
our group and from France, 18–25% of HBeAg-nega-
tive chronic HBV patients with persistently normal
ALT have HBV DNA >2000 IU/ml (<20,000 IU/ml
in the vast majority of them) [5,6], but histological le-
sions justifying therapeutic intervention are rather
rarely present in such cases [6,7]. In fact, even when
a liver biopsy showed changes fulﬁlling the histological
criteria for therapeutic intervention (Pmoderate necro-
inﬂammation and/or moderate ﬁbrosis), this was al-
most always due to the presence of moderate ﬁbrosis
accompanied by minimal necroinﬂammation [6,7]. In
our opinion, which is based on reasonable clinical
judgment, treatment should be given to chronic HBV
patients with some degree of both necroinﬂammation
and ﬁbrosis. By such an approach, we may avoid
unnecessary treatment in chronic HBV patients who
do not actually require therapy, such as inactive
chronic HBV carriers without hepatitis activity but
with some ﬁbrosis accumulated during the HBeAg
seroconversion phase in the past. All reports about sig-
niﬁcant histological lesions in a substantial proportion
of HBeAg-negative patients with persistently normal
ALT come from non-European (usually Asian) studies
including patients with diﬀerent viral and host genetic
characteristics and under a less strict biochemical fol-
low-up [8]. According to the above data [6,7], the
majority of European HBeAg-negative patients with
persistently normal ALT and HBV DNA >2000 IU/
ml will not beneﬁt from a liver biopsy which will show
no or minimal necroinﬂammatory changes (perhapswith some inactive ﬁbrosis in a minority of them) that
do not require therapeutic intervention [1].
In conclusion, a strict adherence to the recommenda-
tion for liver biopsy in all chronic HBV patients with
either abnormal ALT or HBV DNA >2000 IU/ml will
substantially increase the numbers of biopsies in both
HBeAg-positive and HBeAg-negative patients without
increasing the numbers of patients requiring treatment.
Of course, all chronic HBV patients who remain un-
treated, irrespective of having a liver biopsy or not,
should be followed for life. The need for life-long close
follow-up may be further stressed in the guidelines that
should always include strong and speciﬁc recommenda-
tions on the most widely accepted optimal follow-up for
the various groups of untreated chronic HBV patients.
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